CN107881158B - Ube2t肽及包含它们的疫苗 - Google Patents

Ube2t肽及包含它们的疫苗 Download PDF

Info

Publication number
CN107881158B
CN107881158B CN201711214045.9A CN201711214045A CN107881158B CN 107881158 B CN107881158 B CN 107881158B CN 201711214045 A CN201711214045 A CN 201711214045A CN 107881158 B CN107881158 B CN 107881158B
Authority
CN
China
Prior art keywords
peptide
ube2t
seq
cancer
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201711214045.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107881158A (zh
Inventor
角田卓也
大泽龙司
吉村祥子
渡边朝久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN107881158A publication Critical patent/CN107881158A/zh
Application granted granted Critical
Publication of CN107881158B publication Critical patent/CN107881158B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
CN201711214045.9A 2012-09-11 2013-09-09 Ube2t肽及包含它们的疫苗 Expired - Fee Related CN107881158B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699550P 2012-09-11 2012-09-11
US61/699,550 2012-09-11
CN201380047407.3A CN104619833B (zh) 2012-09-11 2013-09-09 Ube2t肽及包含它们的疫苗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380047407.3A Division CN104619833B (zh) 2012-09-11 2013-09-09 Ube2t肽及包含它们的疫苗

Publications (2)

Publication Number Publication Date
CN107881158A CN107881158A (zh) 2018-04-06
CN107881158B true CN107881158B (zh) 2021-11-16

Family

ID=50277926

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711214045.9A Expired - Fee Related CN107881158B (zh) 2012-09-11 2013-09-09 Ube2t肽及包含它们的疫苗
CN201380047407.3A Expired - Fee Related CN104619833B (zh) 2012-09-11 2013-09-09 Ube2t肽及包含它们的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380047407.3A Expired - Fee Related CN104619833B (zh) 2012-09-11 2013-09-09 Ube2t肽及包含它们的疫苗

Country Status (17)

Country Link
US (2) US10092634B2 (enExample)
EP (1) EP2895600B1 (enExample)
JP (1) JP6283861B2 (enExample)
KR (1) KR102110873B1 (enExample)
CN (2) CN107881158B (enExample)
AU (1) AU2013317194B2 (enExample)
BR (1) BR112015004349B1 (enExample)
CA (1) CA2873155C (enExample)
DK (1) DK2895600T3 (enExample)
ES (1) ES2784862T3 (enExample)
IL (1) IL236690B (enExample)
MX (1) MX362912B (enExample)
PL (1) PL2895600T3 (enExample)
RU (1) RU2663350C2 (enExample)
SG (2) SG10201701866QA (enExample)
TW (1) TWI632162B (enExample)
WO (1) WO2014041784A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7572700B2 (ja) 2015-10-19 2024-10-24 ユニバーシティ オブ メリーランド ボルチモア 改変ヒト初代血液樹状細胞株を生成するための方法
JP6715004B2 (ja) 2015-12-25 2020-07-01 宏 半田 免疫賦活化剤およびその製造方法
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
EP3691662A4 (en) * 2017-10-06 2021-05-12 The University of Chicago Screening of t lymphocytes for cancer-specific antigens
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113679829B (zh) 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796184A (zh) * 2007-06-27 2010-08-04 肿瘤疗法科学股份有限公司 治疗癌症的组合物及方法
CN102215870A (zh) * 2008-09-18 2011-10-12 学校法人庆应义塾 癌症的诊断方法和治疗方法
CN102459314A (zh) * 2009-05-11 2012-05-16 肿瘤疗法科学股份有限公司 Ttk肽及包含它们的疫苗

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
EE200100203A (et) 1998-10-05 2002-10-15 M & E Biotech A/S Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
WO2002010369A1 (en) * 2000-07-31 2002-02-07 Kyogo Itoh Tumor antigen
TW200512298A (en) 2003-09-24 2005-04-01 Oncotherapy Science Inc Method of diagnosing breast cancer
US20070202109A1 (en) 2003-09-24 2007-08-30 Oncotherapy Science, Inc. Method Of Diagnosing Breast Cancer
WO2008102906A1 (en) 2007-02-20 2008-08-28 Oncotherapy Science, Inc. Hspc-hrpc transition genes
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
RU2011130796A (ru) 2008-12-24 2013-01-27 Онкотерапи Сайенс, Инк. Пептиды c1orf59 и содержащие их вакцины
TW201216982A (en) 2010-10-21 2012-05-01 Oncotherapy Science Inc WDHD1 peptides and vaccines including the same
AU2011319353A1 (en) 2010-10-21 2013-06-13 Oncotherapy Science, Inc. C18orf54 peptides and vaccines including the same
TWI618541B (zh) 2010-12-02 2018-03-21 腫瘤療法 科學股份有限公司 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796184A (zh) * 2007-06-27 2010-08-04 肿瘤疗法科学股份有限公司 治疗癌症的组合物及方法
CN102215870A (zh) * 2008-09-18 2011-10-12 学校法人庆应义塾 癌症的诊断方法和治疗方法
CN102459314A (zh) * 2009-05-11 2012-05-16 肿瘤疗法科学股份有限公司 Ttk肽及包含它们的疫苗

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Elevated expression of UBE2T in lung cancer tumors and cell lines;Hao J.等;《Tumour Biol.》;20080731;第29卷(第3期);第195-203页 *
Hao J.等.Elevated expression of UBE2T in lung cancer tumors and cell lines.《Tumour Biol.》.2008,第29卷(第3期), *
UBE2T Is the E2 in the Fanconi Anemia Pathway and Undergoes Negative Autoregulation;Yuichi J. Machida 等;《Molecular Cell》;20060818;第23卷;第589-596页 *
Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells;Tomomi Ueki等;《Cancer Res》;20091115;第69卷(第22期);第8752-8760页 *

Also Published As

Publication number Publication date
KR20150054710A (ko) 2015-05-20
MX2015003017A (es) 2015-06-10
TWI632162B (zh) 2018-08-11
PL2895600T3 (pl) 2020-10-05
BR112015004349A2 (pt) 2017-08-08
EP2895600A4 (en) 2016-05-04
US20180360938A1 (en) 2018-12-20
ES2784862T3 (es) 2020-10-01
RU2015113436A (ru) 2016-11-10
CN107881158A (zh) 2018-04-06
BR112015004349B1 (pt) 2022-11-01
EP2895600B1 (en) 2020-02-19
AU2013317194B2 (en) 2018-07-12
JP2015529219A (ja) 2015-10-05
CA2873155C (en) 2022-07-26
IL236690A0 (en) 2015-02-26
CN104619833A (zh) 2015-05-13
US11266729B2 (en) 2022-03-08
TW201414752A (zh) 2014-04-16
EP2895600A1 (en) 2015-07-22
KR102110873B1 (ko) 2020-05-14
DK2895600T3 (da) 2020-04-27
MX362912B (es) 2019-02-22
SG10201701866QA (en) 2017-04-27
IL236690B (en) 2021-03-25
HK1212730A1 (en) 2016-06-17
AU2013317194A1 (en) 2015-02-05
RU2663350C2 (ru) 2018-08-03
US20150174223A1 (en) 2015-06-25
US10092634B2 (en) 2018-10-09
JP6283861B2 (ja) 2018-02-28
SG11201501761SA (en) 2015-04-29
CN104619833B (zh) 2018-01-02
WO2014041784A1 (en) 2014-03-20
CA2873155A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
CN105164256B (zh) Kntc2肽及包含它们的疫苗
US11266729B2 (en) UBE2T peptides and vaccines containing the same
US9849166B2 (en) TOPK peptides and vaccines including the same
US8871719B2 (en) Modified MELK peptides and vaccines containing the same
CN105601727B (zh) Hjurp肽及包含它们的疫苗
CN103189510B (zh) Ttll4肽及包含它们的疫苗
US8697631B2 (en) TMEM22 peptides and vaccines including the same
WO2012053206A1 (en) Wdhd1 peptides and vaccines including the same
KR20130138803A (ko) C18orf54 펩티드 및 이를 포함한 백신
WO2014106886A1 (en) Cdca5 peptides and vaccines containing the same
HK1251236B (en) Topk peptides and vaccines including the same
HK1212730B (en) Ube2t peptides and vaccines containing the same
HK1176365B (en) Modified melk peptides and vaccines containing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211116

CF01 Termination of patent right due to non-payment of annual fee